Asad Zaman

Cardiotoxicity and safety of zanubrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a real-world retrospective cohort study using the TriNetX registry

Abstract Background Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults in the Western countries. Ibrutinib, a first-generation Bruton’s tyrosine kinase (BTK) inhibitor, is commonly used for relapsed/refractory CLL but is associated with cardiovascular adv...